Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis

Trial Profile

Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Adenomyosis
  • Focus Therapeutic Use
  • Acronyms FRA-IIT-UPA
  • Most Recent Events

    • 23 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 08 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017, according to ClinicalTrials.gov record.
    • 08 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top